A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 9, 2012, Pages 1269-1277

  Saida, T ^a,b,c   Kikuchi, S ^d   Itoyama, Y ^e   Hao, Q ^b   Kurosawa, T ^f   Nagato, K ^g   Tang, D ^h   Zhang Auberson, L ^h   Kira, J ⁱ  

^a Kyoto Miniren Central Hospital   (Japan)

^b Institute of Neurotherapeutics   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^f NOVARTIS PHARMA K K   (Japan)

^g MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ KYUSHU UNIVERSITY   (Japan)

Author keywords

fingolimod; multiple sclerosis; randomized clinical trial; sphingosine 1 phosphate receptor

Indexed keywords

FINGOLIMOD; GADOLINIUM; LIVER ENZYME; PLACEBO;

ADULT; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHITIS; CARDIOVASCULAR DISEASE; CONSTIPATION; CONTROLLED STUDY; DENTAL CARIES; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTRITIS; HEADACHE; HUMAN; INFECTION; JAPANESE; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE SCLEROSIS; NAUSEA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; TINEA PEDIS; TREATMENT OUTCOME;

EID: 84866021501     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511435984     Document Type: Article

References (19)

1. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: Therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009 ; 158: 1173-1182
2. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010 ; 33: 91-101
3. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
4. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
5. FrancisGCollinsWBurtinP. Fingolimod (NDA 22-527) Briefing Document: Prepared by Novartis Pharmaceuticals for the Peripheral and Central Nervous System Drugs Advisory Committee Meeting 10 June 2010 (online). Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM214675.pdf (accessed 14 January 2010).
6. Scott SA, Khasawneh R, Peter I, et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010 ; 11: 781-791
7. Satoh T. Genetic polymorphism in drug metabolism and toxicity: Linking animal research and risk assessment in man. AATEX. 2007 ; 14: 443-445
8. Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: Comparison between British and Japanese patients. J Neurol Sci. 1981 ; 49: 253-271
9. Kuroiwa Y, Igata A, Itahara K, et al. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology. 1975 ; 25: 845-851
10. Saida T, Tashiro K, Itoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study. Neurology. 2005 ; 64: 621-630
11. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
12. ICH harmonised tripartite guidelines for good clinical practice E6(R1). International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use, Geneva (1996) http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1-Guideline.pdf (accessed January 12 2011).
13. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. www.wma.net/en/30publications/ 10policies/b3/index.html (accessed 19 October 2010).
14. Nakashima I, Fukazawa T, Ota K, et al. Two subtypes of optic-spinal form of multiple sclerosis in Japan: Clinical and laboratory features. J Neurol. 2007 ; 254: 488-492
15. Ann Neurol. Polman CH Reingold SC Edan G, ed. 2005: 840-846.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
17. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 ; 355: 1124-1140
18. Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010 ; 16: 197-207
19. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007 ; 115: 84-105